Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Emanuel

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
American Journal of Human Genetics|December 17, 2005
Diversity and functional consequences of germline and somatic PTPN11 mutations in human diseaseMarco Tartaglia, Simone Martinelli, Lorenzo Stella, et al.
Blood Advances|April 19, 2018
M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansionYi Luo, Lijian Shao, Jianhui Chang, et al.
Blood Advances|August 11, 2020
Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age-specific mouse modelNitza Vara, Yuqing Liu, Yan Yan, et al.
Blood|November 15, 2007
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaSophie Archambeault, Nikki J Flores, Ayami Yoshimi, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Blood|June 2, 2005
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative diseaseChristian P Kratz, Charlotte M Niemeyer, Robert P Castleberry, et al.
Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.
Blood|December 3, 2003
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesisMignon L Loh, Shashaank Vattikuti, Suzanne Schubbert, et al.
Blood|November 15, 2014
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemiaElliot Stieglitz, Camille B Troup, Laura C Gelston, et al.
Blood Neoplasia|August 27, 2025
Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletionsTamara Westover, Michael P Walsh, Sherif Abdelhamed, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
American Journal of Human Genetics|December 17, 2005
Diversity and functional consequences of germline and somatic PTPN11 mutations in human diseaseMarco Tartaglia, Simone Martinelli, Lorenzo Stella, et al.
Blood Advances|April 19, 2018
M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansionYi Luo, Lijian Shao, Jianhui Chang, et al.
Blood Advances|August 11, 2020
Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age-specific mouse modelNitza Vara, Yuqing Liu, Yan Yan, et al.
Blood|November 15, 2007
Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemiaSophie Archambeault, Nikki J Flores, Ayami Yoshimi, et al.
British Journal of Haematology|January 4, 2014
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemiaMichael W Deininger, Kenneth J Kopecky, Jerald P Radich, et al.
Blood|June 2, 2005
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative diseaseChristian P Kratz, Charlotte M Niemeyer, Robert P Castleberry, et al.
Pediatric Blood & Cancer|February 24, 2015
Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology GroupElliot Stieglitz, Ashley F Ward, Robert B Gerbing, et al.
Blood|December 3, 2003
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesisMignon L Loh, Shashaank Vattikuti, Suzanne Schubbert, et al.
Blood|November 15, 2014
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemiaElliot Stieglitz, Camille B Troup, Laura C Gelston, et al.
Blood Neoplasia|August 27, 2025
Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletionsTamara Westover, Michael P Walsh, Sherif Abdelhamed, et al.
Pageof 5